Therefore, while p300 is thought of as a classic tumour suppressor, with loss of function mutations occurring in a number of different cancers100, constitutive activation by mutation or by interaction with activating ligands such as BRD4-NUT and E1A can lead to acetylation-dependent condensation with an oncogenic outcome. The gene discussed is BRD4; the disease is neoplasm.